Trager James
Known title: Chief Scientific OfficerCIK: 0001816549
Associated companies
Transaction History
| NKTX | ▼ Sell | Open Market | 456 | $3K | 6/18/2024 | View on chart |
| NKTX | ▼ Sell | Open Market | 4,143 | $50K | 2/12/2024 | View on chart |
| NKTX | ▼ Sell | Open Market | 4,560 | $40K | 1/16/2024 | View on chart |
| NKTX | ▲ Buy | Grant | 56,000 | $0 | 1/4/2024 | View on chart |
| NKTX | ▼ Sell | Open Market | 439 | $2K | 6/20/2023 | View on chart |
| NKTX | ▼ Sell | Open Market | 1,115 | $6K | 1/17/2023 | View on chart |
| NKTX | ▲ Buy | Grant | 37,500 | $0 | 1/13/2023 | View on chart |
| NKTX | ▲ Buy | Option Exercise | 5,000 | $19K | 8/15/2022 | View on chart |
| NKTX | ▼ Sell | Open Market | 5,000 | $88K | 8/15/2022 | View on chart |
| NKTX | ▲ Buy | Grant | 5,000 | $0 | 6/17/2022 | View on chart |
| NKTX | ▲ Buy | Grant | 12,800 | $0 | 1/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Nkarta Sets 2026 Data Reveal as CAR NK Trials Progress
Nkarta announced that it is targeting a data reveal for its outpatient CAR NK trials in 2026. The company said the trials are advancing, indicating progress toward a potential regulatory milestone. This development may influence how the market views the company’s future prospects. The stock is currently trading near its support level of $2.61.
Nkarta Sets 2026 Data Reveal as CAR NK Trials Progress. Nkarta announced that it is targeting a data reveal for its outpatient CAR NK trials in 2026. The company said the trials are advancing, indicating progress toward a potential regulatory milestone. This development may influence how the market views the company’s future prospects. The stock is currently trading near its support level of $2.61.